Thirdly, among interventions that target the microbiome are probiotics, prebiotics, SCFA supplementation, dietary modifications (e.g., Mediterranean diets or those rich in fibers), FMT, and emerging LBPs, all of which combine toward what could be considered a promising frontier in therapeutic potential
Table 1 summarizes major metabolic disturbances and candidate cell-therapy effects
(Exenatide is FDA approved as monotherapy for the management of T2DM.) Explicitly stated in the guideline for patients requiring dual or triple therapy, the AACE/ACE preferentially recommends the addition of a GLP-1 receptor agonist or a DPP-4 inhibitor (sitagliptin, saxagliptin), citing their efficacy and safety profiles as preferred agents over TZDs or sulfonylureas (SUs)
Clostridium butyricum - produces the postbiotic butyrate which stimulates GLP-1
Its essential to avoid situations that use up lots of energy (like fasting) as that can trigger the condition
So are ours as well as those of Rose et al